Wyeth v. Levine and Its Implications

Brian Wolfman

Georgetown University Law Center

May 11, 2009

Product Safety & Liability Report (BNA), Vol. 37, pp. 550-558, 2009
Georgetown Public Law Research Paper No. 12-138

The U.S. Supreme Court’s decision in Wyeth v. Levine sharply limited the availability of implied preemption as a defense in pharmaceutical cases. In this Analysis & Perspective, attorney Brian Wolfman discusses the decision and its implications for prescription drug litigation as well as litigation in other areas that are regulated by the federal government.

After Wyeth, Wolfman says, a defendant in a prescription drug case must demonstrate a ‘‘tight fit between the labeling change proposed by the manufacturer (and rejected by the FDA) and the labeling change that the plaintiff contends would have prevented her injuries.’’ Moreover, he says, in light of Wyeth, agency claims of preemption with respect to other products or services are likely to be subject to increased judicial scrutiny, and it is unlikely that these claims will be accorded substantial deference unless they are tethered to a congressional authorization regarding preemption.

Number of Pages in PDF File: 10

Keywords: Wyeth v. Levine, FDA, preemption, pharmaceutical cases, Supreme Court, CBE regulation, drug labeling

JEL Classification: K00, K30, K39

Open PDF in Browser Download This Paper

Date posted: September 22, 2012  

Suggested Citation

Wolfman, Brian, Wyeth v. Levine and Its Implications (May 11, 2009). Product Safety & Liability Report (BNA), Vol. 37, pp. 550-558, 2009; Georgetown Public Law Research Paper No. 12-138. Available at SSRN: https://ssrn.com/abstract=2150325

Contact Information

Brian Wolfman (Contact Author)
Georgetown University Law Center ( email )
600 New Jersey Avenue, NW
Washington, DC 20001
United States
Feedback to SSRN

Paper statistics
Abstract Views: 354
Downloads: 21